Why Indian drugmakers are losing pricing power in the US
Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment before they can replace lost revenue.
Indian pharmaceutical companies are witnessing a decline in their pricing power within the United States, their most significant market. This decline is attributed to concentration among buyers and heightened competition, which has led to a reduction in sales and margins. In the July-September 2026 quarter, Cipla's North American revenue experienced a 19% decrease in rupee terms, primarily due to a decline in the sales of its generic Revlimid, a medication used to treat blood cancer.
Revlimid also impacted Dr. Reddy's North American sales, while Lupin's sales in the United States declined by 13% from the April-June quarter after losing exclusivity on Tolvaptan and Mirabegron.
Written by urgent.news from Live Mint's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.